Mural Oncology PLC Logo

Mural Oncology PLC

Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.

MURA | BUD

Overview

Corporate Details

ISIN(s):
IE000LK2BOB4
LEI:
Country:
Ireland
Address:
N/A
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Mural Oncology PLC is a clinical-stage oncology company focused on developing novel immunotherapies to treat cancer. The company leverages its proprietary protein engineering platform and expertise in cytokine biology to design and advance a pipeline of cytokine-based therapies. Its mission is to unlock the value of immunotherapy for a broader range of patients, particularly those with cancers that have not responded to previous treatments. The company's lead candidate, nemvaleukin alfa, is a novel, engineered interleukin-2 (IL-2) variant immunotherapy currently in clinical trials for difficult-to-treat solid tumors, including advanced melanoma and platinum-resistant ovarian cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-24 22:25
Post-Annual General Meeting Information
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisiti…
English 31.3 KB
2025-09-24 01:52
Proxy Solicitation & Information Statement
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement …
English 18.3 KB

Automate Your Workflow. Get a real-time feed of all Mural Oncology PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mural Oncology PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mural Oncology PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.